Centessa Pharmaceuticals plc - ADR
CNTA | $10.53 -2.32% -1.99% 110K
|
Manufacturing
(0.0% 1d) (-6.8% 1m) (122.4% 1y) (0.0% 2d) (0.0% 3d) (2.3% 7d) (171.77% volume)
Earnings Calendar:
Market Cap: $ 1,056,220,600
https://www.centessa.com
Sec Filling | Patents | 2021 employees
Centessa Pharmaceuticals plc aims to bring impactful new medicines to patients by combining the strengths of an asset-centric model with the benefits of scale and diversification typical of larger R&D organizations. The asset-centric model refers to a highly specialized, singular-focused company that is led by a team of well-recognized subject matter experts. Centessa wholly owns ten of these asset-centric companies. The companies’ programs range from discovery-stage to late-stage development and include diverse therapeutic areas such as oncology, hematology, immunology/inflammation, neuroscience, hepatology, pulmonology and nephrology. Centessa’s asset-centric companies are overseen by the Centessa management team, which sets overall strategy and direction, provides leadership and expertise, and manages resource allocation and shared infrastructure.
urea ycombinator
add to watch list Paper trade email alert is off
Press-releases
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023
Published: 2024-03-28 (Crawled : 21:00) - globenewswire.com
CNTA | $10.53 -2.32% -1.99% 110K
|
Manufacturing
| Email alert
Add to watchlist
business pharmaceuticals financial results
Centessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference
Published: 2024-02-22 (Crawled : 13:30) - globenewswire.com
CNTA | $10.53 -2.32% -1.99% 110K
|
Manufacturing
|
| O: 0.96%
H: 7.81%
C: 2.38%
conference health care pharmaceuticals
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
Published: 2024-02-09 (Crawled : 12:00) - globenewswire.com
CNTA | $10.53 -2.32% -1.99% 110K
|
Manufacturing
|
| O: 20.64%
H: 4.49%
C: 2.89%
haemophilia congress association year disorders treatment ongoing pharmaceuticals study
Centessa Pharmaceuticals to Present at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
Published: 2024-02-09 (Crawled : 15:30) - biospace.com/
CNTA | $10.53 -2.32% -1.99% 110K
|
Manufacturing
|
| O: 20.64%
H: 4.49%
C: 2.89%
haemophilia congress association disorders pharmaceuticals
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
Published: 2024-01-22 (Crawled : 13:00) - globenewswire.com
CNTA | $10.53 -2.32% -1.99% 110K
|
Manufacturing
|
| O: 0.49%
H: 4.3%
C: 0.0%
pharmaceuticals
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences - January 22, 2024
Published: 2024-01-22 (Crawled : 14:30) - biospace.com/
CNTA | $10.53 -2.32% -1.99% 110K
|
Manufacturing
|
| O: 0.49%
H: 4.3%
C: 0.0%
pharmaceuticals
Centessa Pharmaceuticals to Present at the 42ⁿᵈ Annual J.P. Morgan Healthcare Conference
Published: 2023-12-13 (Crawled : 13:00) - globenewswire.com
CNTA | $10.53 -2.32% -1.99% 110K
|
Manufacturing
|
| O: 1.41%
H: 4.47%
C: 2.47%
conference pharmaceuticals
Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia
Published: 2023-12-10 (Crawled : 20:20) - globenewswire.com
CNTA | $10.53 -2.32% -1.99% 110K
|
Manufacturing
| Email alert
Add to watchlist
year treatment ongoing pharmaceuticals study
Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals
Published: 2023-11-27 (Crawled : 21:00) - globenewswire.com
CNTA | $10.53 -2.32% -1.99% 110K
|
Manufacturing
|
| O: -1.69%
H: 1.78%
C: -6.1%
ANAB | $19.83 -7.64% -8.32% 360K
|
Health Technology
|
| O: 0.0%
H: 2.45%
C: -0.36%
antibody license pipeline cell pharmaceuticals
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023
Published: 2023-11-13 (Crawled : 21:00) - globenewswire.com
CNTA | $10.53 -2.32% -1.99% 110K
|
Manufacturing
|
| O: 3.85%
H: 5.25%
C: 2.31%
business pharmaceuticals financial results
Last 15 days Sec forms
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 60% | 40% |
Top 10 Gainers
AGBA | News | $1.03 157.5% 57.94% 120M
|
Finance
ZCMD | $1.45 5.84% 52.1% 2.3M
|
Commercial Services
INVO | $1.52 100.0% 51.13% 5M
|
Health Technology
ISPC | $0.421 97.65% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.5 45.65% 470K
|
OST | $0.509 23.81% 45.26% 90K
|
GDHG | $0.263 21.76% 40.66% 3.1M
|
XPON | News | $3.15 63.21% 37.74% 16M
|
TIRX | $0.8 65.02% 30.74% 58M
|
BNTC | News | $6.82 42.08% 30.64% 3.5M
|
Health Technology
Last 48 Hours Insiders Buying
ADMQ | $0.0532 -4.14% -40.18% 480K
|
|
10:30
AXR P 2400 | $22.17 2.69% 0.0% 5.5K
|
Finance
|
21:00
QCRH P 118 | $55.41 1.34% 1.31% 54K
|
Finance
|
18:01
VUZI P 7500 | $1.26 3.28% 3.17% 930K
|
Electronic Technology
|
18:00
RMCF | $3.5501 0.57% 2.22% 18K
|
Consumer Non-Durables
|
20:10